Revance Therapeutics Inc (RVNC)

[Dennboy66]

Closed above 3. Well what do you know? :).
Does anyone know if Dew is still invested in RVNC?

[alertmeipp]

I am trying as hard as possible to ignore all these tiny moves

Either Daxxify works as advertised and will eventually take significant portion of the market and RVNCs earning per share will be > than current stock price a few years out


Or

It’s a write off.


At current price, the market pretty much written it off already so any upside is free.

But I am the one who thought 8 9 bucks thinking it’s good risk and reward ratio

So what do I know lol

[stocksrising]

this move probably associated with Tobin speaking tomorrow.. a positive commentary is what we need by him, then Foley next week :) DAH

[alertmeipp]

The moment RVNC can show the market its sales is gaining traction, share price will take off exponentially.

For now, it’s a waiting game.

[go seek]

Now offering RHA and DAXXIFY
https://www.instagram.com/p/C7rpWOGJipN/?igsh=eTE2M2x5NTlqNmRy

https://www.instagram.com/p/C6FAjBpvRQ6/?igsh=dGxubHA4Zmo5bnJz

https://www.instagram.com/p/C5t_LjGRCM7/?igsh=MXV1NTY0dHFlb3kxNA==

[biotech_researcher]

I expected your nebulous, non factual, without substance post, and you sure didn’t disappoint me.

[IanFromSI]

You have obviously never had any form of management position in any corporation, large or small.

That was the most irrelevant observation I have ever seen even on iHub.

[biotech_researcher]

Ian, you are delusional if you think RVNC can’t recover from this misstep in their launch. Go Seek is showing us the pathway that is now in full swing, and it has nothing to do with management presentations across the land. It is good old fashion word of mouth testimonials from patients that have been treated and show their “glowing” results.

[biotech_researcher]

Go seek, thanks again for rounding these up. It is interesting that your last link for Innova, which is in Ocala, FL, which is quite rural, farms and horses, and not cosmopolitan at all.

[biotech_researcher]

Allergan knows their days are numbered with Botox, so they wanna capture as much revenue upfront as they can

[alertmeipp]

Love to hear they are cutting fat and I don’t think that means they are slowing down on aesthetic side. They just need to be way more cost effective.

After they slash the price, Daxxify is really a no brainer product to sell, word of mouth will do the job hundreds of sales do

[AXRX4952]

base pay is a lower now so it's a lot of younger reps who are hungry to get into "aesthetics" any way they can. Not many are left from the initial hire in 2020 when RHA first launched and the sales force became active. Comp plan changes quarterly and most tenured reps will not put up with the goal post moving every 90 days. RVNC sales force has been through the ringer from Covid shut downs, to the Daxi CRL delay of 1 year and then a failed launch of Daxi. They all came to sell Daxi and make a big splash and that wave never came to fruition. This is well known to injectors who have had multiple reps in a short time.

[vinmantoo]

Wow! Talk about changing the subject.

Deflectors on maximum. I didn't change the subject. You did. I then responded to your post where you changed the subject. I guess I have to do that again since you changed the subject again.

I have witnessed a few perms-bulls who’ve been told Daxxi is by far the best, and they believed that all toxin customers will come and buy it, regardless of price, Support or training of the injectors. they seem to have expected 100% market share in any market that they entered almost immediately.

I believe most of them now suspect that that belief was unfounded and far from the truth. …. Even if they have to look at the stock price daily to remind them of that fact.

Yet another changing of the subject. You seem to be angry at others and attributing their errors or comments to me. I never expected or stated that I expected Daxxify to achieve anything close to 100% market share any time soon. I doubt that doubt anyone expected that. Have Daxxify sales been slower than I had hoped or expected so is reflected in a low share price? Obviously.

… and you’re still the guy who thought it’s a wonderful idea to buy some stock now because you expected to sell it and be able to use it to offset all of your capital gains. …. Clearly not a very effective strategy for getting rich quick. …. But you certainly were able to implement the strategy very very quickly. I didn’t expect your vision would become reality anywhere near this fast

You have it backwards. I have twice sold stock I bought earlier at a higher price to get short term tax losses and both times was able to buy back at lower prices. I will spell it out for you. I have increased my overall share total WITHOUT spending ANY more money out of pocket. It isn't get rich quick scheme. It seems I need to explain to you that it is a common method of generating capital losses to cut capital gains. I am just about at the point where I have generated enough SHORT-term capital losses to offset SHORT-term capital gains. You do realize that short-term gains are taxed at a higher rate than long-term gains, right. Thankfully, my long term gains are far in excess of any long term losses.

As far as get rich quick, I don't invest with that viewpoint. Would I prefer that RVNC be trading at a much higher stock price? Obviously, but these things take time and I can afford to wait as I have a large free cash pool and a lot of patience. You seem to be more of a short-term get rich quick investor than I am. Good luck to you.

[Aestheticexec]

And BTX cosmetic has lost aesthetic share. Fact.

They raised prices because of therapeutics and the segment of cosmetic consumers who will always ask and pay for Botox by name. Therapeutic demand is less elastic

[Tomdontworry]

Do you see quality sales people joining?

[go seek]

OT Dreamers vs Doers
https://www.instagram.com/reel/C4wSiGXuPh-/?igsh=MWkyZXFlazNiNHl2dQ==

[AXRX4952]

That's incorrect. Teoysal RHA has been global since 2015. Teoysal has many different lines and RHA is the newest line which is why Revance became a distributor and brought it to the states. Teoysal Puresense is the older fillers globally and Revance chose not to start with those in USA. You can find all the details on their website. https://www.teoxane.com/en

[AXRX4952]

that's basically what is happening. Most all of the expansion reps from April 2023 have quit and were not replaced, more reps quit and territories were "re-aligned". Regions have been consolidated. Nashville floors have been offered for sublease since last year.... Filler Marketing folks have move on or over to Daxi CD. It's already a skeleton crew on the aesthetics side as of last year... they still have more fast to trim...

[IanFromSI]

Wow! Talk about changing the subject.

I have witnessed a few perms-bulls who’ve been told Daxxi is by far the best, and they believed that all toxin customers will come and buy it, regardless of price, Support or training of the injectors. they seem to have expected 100% market share in any market that they entered almost immediately.

I believe most of them now suspect that that belief was unfounded and far from the truth. …. Even if they have to look at the stock price daily to remind them of that fact.

… and you’re still the guy who thought it’s a wonderful idea to buy some stock now because you expected to sell it and be able to use it to offset all of your capital gains. …. Clearly not a very effective strategy for getting rich quick. …. But you certainly were able to implement the strategy very very quickly. I didn’t expect your vision would become reality anywhere near this fast.

The issue is managerial competence.

RVNC is a company with about 600 full-time employees.

Revance Therapeutics, Inc.’s ISS Governance QualityScore as of May 29, 2024 is 6. The pillar scores are Audit: 6; Board: 5; Shareholder Rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

In contrast, NVO with about 66,000 employees is much better.

Novo Nordisk A/S’s ISS Governance QualityScore as of May 29, 2024 is 2. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 9; Compensation: 1.

Before the Dax rollout started, I suggested to this board that Abbvie would not roll over and play dead. But a small and very vocal subset of the 151 members that follow this board knew much better than everybody else and expected that whatever they said on this board would be seen by the whole world, and their sage advice would lead to 100% market share in no time at all. …. And, of course, everyone buying RVNC shares.

… and I suspect people like Deming or Rummler-Brache, or terms like quality improvement are relatively unknown in RVNC or on this board.


Unless I see signs that RVNC has brought in an effective management/sales team, which has successfully ruled out its first product into an established competitive environment, I think the risk is that RVNC will fail.

Nothing that I say on this board will be seen by anyone who can change that result one way or the other

I do hope that prospective buyers will read this posting and many others to get a more complete picture before being sucked into a sure thing.

FWIW

[go seek]

I Love DAXXIFY! Dr. Jason Pozner
https://www.instagram.com/reel/C7ohkh9pKBi/?igsh=MWtrc2dtcXVpZGxuag==

https://www.instagram.com/p/C7m8BI_uyQT/?igsh=MTc4ZDBqOTY0YmNpbA==

https://www.instagram.com/p/C6FAjBpvRQ6/?igsh=dGxubHA4Zmo5bnJz

https://www.instagram.com/p/C7CCxrnNlKV/?igsh=cm1uc2U3ZW5ieDBl

[vinmantoo]

Let me see if I can get this straight

Based on what you just wrote, I have my doubts that you can.

Daxxify starts with a premium priced product. Its sales suck. RVNC lowers the price significantly. ABBV Raises the price.

Does this really sound as if Botox is worried about Daxxify is taking market share?

I was responding to the ludicrous claim that toxin aesthetics is a race to the bottom by stating that a race to the bottom wouldn't see the leader raise prices. That is correct and I stand by it. You responded with what I assume in your mind was a cutting rebuttal but is in reality a different question.

RVNC did fumble the initial launch by charging a PREMIUM price in the faulty assumption that the longer lasting Daxxify would grab market share. That approach failed so RVNC cut their prices to attack customers and are now slowly seeing an increase in customers. RVNC still have a very small market share so Allergan decided they could increase the Boxox price by 10% and make more money. They will indeed make more money as long as they don't lose 10% of their market share any time soon. I doubt Daxxify will take 10% more of the market share in the next few months or even quarters so it will remain a money maker for Allergan for a while. Capisce?

[IanFromSI]

You don't seem to understand what race to the bottom means. ABBV/Allergan RAISED the price of Botox either late last year or early this year. That doesn't happen in a race to the bottom.

===================================

Let me see if I can get this straight!

Daxxify starts with a premium priced product. Its sales suck. RVNC lowers the price significantly. ABBV Raises the price.

Does this really sound as if Botox is worried about Daxxify is taking market share?

[biotech_researcher]

Glad you are not responsible for running a business.. no clue

[vinmantoo]

Aesthetics is a race to the bottom. Show me data otherwise.

Race to the bottom?? Bbbbwwwaaaa hhhaaaaa. You don't seem to understand what race to the bottom means. ABBV/Allergan RAISED the price of Botox either late last year or early this year. That doesn't happen in a race to the bottom.

Aesthetics is a large market and Daxxify is starting to gain market share there. For some reason you want RVNC to throw that away. Wow!! The market for therapeutics is indeed large and Daxxify can grab a major part of that.

[alertmeipp]

Funny how you make a baseless claim and ask others to provide data

Maybe u should provide data for your own claim first?

[Aestheticexec]

Aesthetics is a race to the bottom. Show me data otherwise. Look at rest of world. I’m interested in one thing only - increasing share price.

[vinmantoo]

DAXI for aesthetics should be run by a skeleton crew of reps and marketing programs (75-100 reps, coupon programs, and CME programs on 1:1 and 2:1 BTX dosing). Shut down Nashville. Move every other head and promotional dollar to therapeutic.

Thankfully you have nothing to do with RVNC's management.

[Aestheticexec]

DAXI for aesthetics should be run by a skeleton crew of reps and marketing programs (75-100 reps, coupon programs, and CME programs on 1:1 and 2:1 BTX dosing). Shut down Nashville. Move every other head and promotional dollar to therapeutic. CME programs on dosing other therapeutic indications.

[go seek]

Switched to DAXXIFY
https://www.instagram.com/p/C6zA0IcuNPW/?igsh=bjM2N3llYmwwYmIx

[vinmantoo]

EOLS and Jeuveau is a winner. Another reason why therapeutic is where the best opportunity is for Daxxify IMO.

Yes, Allergan and ABBV should be worried about them but not RVNC because it has the superior product.

Yes, Daxxify should be the leader in CD. At least you didn't say RVNC should drop Daxxify for use in aesthetics.

[go seek]

RHA Lip Launch
https://www.facebook.com/share/r/T5VK8iPKKeVypHiF/?mibextid=s54t8k

[go seek]

Foley is not a bad communicator. He does well IMO at conferences and at earnings calls. Of course w the sell off of recent months investors were / are discouraged w management. The company definitely could have done better w the launch. But much (needed) experience and knowledge was gained over the past 18 months. It appears Buyers are coming back.

[usma67korea]

we have 2 investor conference in June. any longer term investors know how Foley is w/ these conferences? usually non event or does he tend to deliver some positives in these conf?

[boraborak38]

ABP-450/ Aeon is a loser. EOLS and Jeuveau is a winner. Another reason why therapeutic is where the best opportunity is for Daxxify IMO.

[10nisman]

this is a dumb take. companies change CEOs all the time - even Apple (Jobs got fired and came back of course). asking for ceo change doesn't mean investors just sell the stock. more often than not, new leadership and visions are needed (not abandoning the company altogether).

It's a dumb take because Company's change their CEO's all the time? Interesting. So, even though you have no ability to actually encourage the Board to make a change (i.e., you don't have activist pull). You're going to keep your position in a small-cap Company for which you think the CEO is doing a horrible job and should be fired, with the hopes the Board replaces him (instead of selling your shares and buying back-in only after a CEO change is made). Not sure your definition of dumb, but I'd call that very dumb.

Based on your above view, you either actually think RVNC is going to succeed no matter who runs the company (Foley or someone new) and you're just a disgruntled investor slamming Foley instead of looking in the mirror, or you have high conviction the Board is going to replace Foley, in the near future, with someone significantly better. Best of luck if you're betting on the later.

[Fact100]

Teoxane's line of fillers is Teoysal in EU and in the US it's RHA, it's the same product. Some of the RHA/Teosyal products have been used in Europe since 2004. Juvederm Ultra and Ultra Plus have been used since 2006. So, both Juvederm and RHA/Teosyal are about 20 years old. The AE's you are referring to with Juvederm are not with the Ultra/Ultra Plus (Hylacross technology) they are with the Vycross technology products (Voluma, Vollure, Vobella).

[Emannow]

RHA is the 2nd generation of Juvederm. Juvederm was sold to Allergan by Valerie Taupin, CEO of Teoxane, 15 plus years ago. Valerie took the Juvederm money and build Teoxane which is a much cleaner product than Juvederm which will soon be 20 years old...same as Botox which is 20 plus years old! RHA is a much cleaner blend HA than Juvederm. Many doctors will not use Juvederm any more because of the many adverse advents...delayed bumps and lumps under the skin!

Restylane is #1 Market share world wide, Juvederm is #2 and RHA is #3 and quickly taking market share from Juvederm.

[alertmeipp]

If RHA and Daxxify get 10 percent of US market, that would be close to 500mm of annual sales

RHA is close to 10 percent already, maybe it can get to 15 percent next year?
Daxxify probably will get up to 5 to 7 percent this year? Then, 10 percent next?

That’s excluding CD and ex US sales


Current EV is 500mm

Lots of option value alone

[go seek]

Yeah! 👍 day for RVNC! (In a down market)
👍

[go seek]

Daxxi is a Home Run!
https://www.instagram.com/reel/C7dhQ0rs4Z4/?igsh=NWt3NGZhdjduOTA0

[YY1000]

That would promote CD from #3 to their lead indication according to their corporate presentation. They still claim P3 for CD will start in 2024, but last P2 patient was dosed in July 2022, so as Dew has pointed out they seem to have de-prioritized CD given RVNC's stellar data. Given that they are practically insolvent that P3 is unlikely to happen.

I don't think ABP-450 was seen as a serious threat in the therapeutic market, but every little bit helps...

[usma67korea]

sorry. my bad. $2.6s.. geez.. 3.6 be 40% higher i guess. i take that of course..

[DewDiligence]

AEON—>55% workforce reduction—ABP-450 clinical development suspended:

https://finance.yahoo.com/news/aeon-biopharma-announces-strategic-reprioritization-120000294.html

Upon securing additional capital, we would be positioned to announce a revised clinical development strategy for our pipeline of ABP-450 programs.

AEON is all but insolvent—see #msg-174417740.

Reminder: ABP-450 is the same drug as EOLS’ Jeuveau, sourced from Korea’s Daewoong.

[IanFromSI]

to hold here in 3.6s.. 3-4 days now...

===============================

Do you mean $2.66 per share?

If not, what does 3.6s mean?

Since the earnings report, RVNC has not seen $3.10 per share.

Warren Buffett will tell you over and over again great companies have fabulous management and fabulous leaders.

Apple recognized it after firing Steve Jobs, then after miserable failures, they rehired him and has been an extraordinary success ever since. …. Including the transition to Tim Cook.

[usma67korea]

is it possible to hold here in 3.6s.. 3-4 days now... amazing how low bar my wishes have become.. hold the $3.6 line seems like i am routing for some clinical microcap bio.

[go seek]

This sell off is overdone. Revenues from DAXXIFY and RHA will increase throughout 2024 and Revance will meet or exceed its $280M revenue target. Thereto RVNC stock will rebound… and move significantly higher.

[vinmantoo]

The markets are closed for the long Memorial day weekend so I have 3 days to count my profit! ;)

The Holiday weekend is over and with it my one day "profit".

[alertmeipp]

So I guess the company is not going under in the next couple weeks at least lol

[Emannow]

Revance Therapeutics Inc at William Blair Growth Stock Conference Jun 04, 2024

Revance Therapeutics Inc at Goldman Sachs Global Healthcare Conference Jun 11, 2024

[alertmeipp]

Have to wonder why the market doesn’t willing to give RVNC at least a few quarters

They are granting market share and getting into more accounts

If you net out RHA, market is paying zip for Daxxify, a drug that’s best in class in a 5 billions plus market